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Due to their rapid and widespread development, DNA vaccines have entered into a variety of human clinical trials for vaccines
against various diseases including cancer. Evidence that DNA vaccines are well tolerated and have an excellent safety proﬁle proved
to be of advantage as many clinical trials combines the ﬁrst phase with the second, saving both time and money. It is clear from the
results obtained in clinical trials that such DNA vaccines require much improvement in antigen expression and delivery methods
to make them suﬃciently eﬀective in the clinic. Similarly, it is clear that additional strategies are required to activate eﬀective
immunity against poorly immunogenic tumor antigens. Engineering vaccine design for manipulating antigen presentation and
processing pathways is one of the most important aspects that can be easily handled in the DNA vaccine technology. Several
approaches have been investigated including DNA vaccine engineering, co-delivery of immunomodulatory molecules, safe routes
of administration, prime-boost regimen and strategies to break the immunosuppressive networks mechanisms adopted by
malignant cells to prevent immune cell function. Combined or single strategies to enhance the eﬃcacy and immunogenicity
of DNA vaccines are applied in completed and ongoing clinical trials, where the safety and tolerability of the DNA platform are
substantiated. In this review on DNA vaccines, salient aspects on this topic going from basic research to the clinic are evaluated.
Some representative DNA cancer vaccine studies are also discussed.
1.Introduction
Spontaneous tumour regression has followed bacterial, fun-
gal, viral, and protozoal infections. Intratumoral infections
may reactivate defensive functions, causing tumour regres-
sion.
These phenomena inspired the development of numer-
ous rudimentary cancer immunotherapies, starting with
nonspeciﬁc immunostimulatory approaches ﬁrst used by
William Coley [1] and leading to the concept of therapeutic
vaccination against cancer. The recent identiﬁcation and
characterization of genes coding for tumour antigens (Ag)
has enabled the design of antigen-speciﬁc cancer vaccines
based on plasmid DNA and recombinant viral vectors. Gene
therapy can be used to manipulate the immune system to
help body’s natural defences to recognise and target cancer
cells.
In the last few years, it is estimated that in Europe there
werealmost3000000 cancercasesdiagnosed (excluding non
melanoma skin cancers) and more than 1500000 deaths
from cancer each year [2]. Standard therapeutic procedures
currently in practice, including surgery, radiation, and
chemotherapy have not greatly impacted the spread and
recurrence of progressive malignancies [3], reducing the
ability of the immune system to provoke “spontaneous”
regressions.Newerstrategiesareneededtoimproveuponthe
current treatment success rate.
Historically, Wolﬀ and colleagues [4] ﬁrst demonstrated
that long-term gene expression in mouse skeletal muscle
could be achieved with direct intramuscular injection of2 Journal of Biomedicine and Biotechnology
plasmid DNA. This and other early studies, demonstrating
the feasibility of direct intramuscular gene transfer for DNA
vaccination purpose, propelled the ﬁrst vaccination studies
utilizing plasmid DNA in protection scenarios involving
inﬂuenza [5]a n dH I V - 1[ 6]. Cellular and humoral immune
responses have been demonstrated after the injection of
naked plasmid DNA vaccines into the dermis or muscle
tissue of mice [5, 7]. Such responses have induced protection
in preclinical models of infectious disease and malignancies
(for review, see Donnelly et al. [8]).
The DNA vaccine is a prime example of a modern
genetic vaccine. The use of naked plasmid DNA as vaccine to
elicit the immune system against disease provides a variety
of practical beneﬁts for large-scale vaccine production that
are not as easily manageable with other forms of vaccines
including recombinant protein or whole tumor cells [9, 10].
The eﬀectiveness to screen for antigens rapidly and to
design speciﬁc types of expression constructs has made the
study of DNA vaccines a valuable ﬁeld for immunotherapy
of cancer.
New technologies including gene-expression proﬁling
has increased the list of candidate tumor antigens. Inves-
tigators have focused on targets which are either tumour-
speciﬁc, including idiotypic antigens of B-cell tumours [11]
ortumour-associatedantigens[12]thatarealsoexpressedby
the normal cell of origin [13] and that include the so-called
cancer-testis antigens [14].
Examples under intensive investigation are the antigens
of melanoma (http://www.cancer.gov/cancertopics/types/
melanoma), prostate cancer (http://www.cancer.gov/cancer
topics/types/prostate), and other epithelial cancers (http://
www.cancer.gov/cancertopics/types/skin).
DNA vaccines oﬀer the opportunity to incorporate addi-
tional genes encoding molecules aimed at overcoming the
weak immunogenicity of tumor antigens and the patients’
tolerized immune repertoire.
This paper brieﬂy summarizes ﬁndings and key tech-
nologies that have contributed to the rapid progress of DNA
vaccines (mode of action, design, and optimization of DNA
vaccines) as well as the state of the art of some of the
more encouraging clinical studies using or against tumor
antigens.
2. Cancer Antigens
Scientists have identiﬁed a large number of cancer-associated
antigens, many of which are now being used to perform
cancer treatment vaccines both in basic research and in
clinical trials. The list of candidate tumor antigens grows
daily, largely because of expanding genetic technology
including human genome sequencing and gene-expression
proﬁling. Tumor antigens have been classiﬁed into two
broad categories: tumor-speciﬁc shared antigens and tumor-
speciﬁc unique antigens [15]. Shared antigens or tumor-
associated antigens (TAAs) are expressed by more than one
type of tumor cells. A number of TAA are also expressed
on normal tissues, albeit in diﬀerent amounts. As reported
in the oﬃcial National Cancer Institute website (NCI,
http://www.cancer.gov/), representative examples of such
shared antigens are the cancer-testis antigens [14], human
epidermal growth factor receptor 2 (HER2)/neu protein
(reviewed in [16]), and carcinoembryonic antigen (CEA)
[17]. Unique tumor antigens result from mutations induced
through physical or chemical carcinogens; they are therefore
expressed only by individual tumors. Tumor-speciﬁc unique
antigens encompass melanocyte/melanoma diﬀerentiation
antigens, such as tyrosinase [18], MART1 [19] and gp100
[20], prostate-speciﬁc antigen (PSA) (reviewed in [21]) and
Idiotype (Id) antibodies [11]. Optimally designed cancer
vaccines should combine the best tumor antigens with the
most eﬀective immunotherapy agents and delivery strategies
toachievepositiveclinicalresults.Animportantdilemmafor
vaccination against overexpressed tumor-associated antigens
is how to induce eﬀective immunity against the chosen
target without leading to damaging autoimmunity. The
precision oﬀered by DNA vaccines will induce focused
immunity against selected antigens, and, as they become
more powerful, targets will have to be selected carefully to
avoid autoimmunity. Recently, an NCI pilot prioritization
study produced a well-vetted, priority-ranked list of cancer
antigens [22]. Antigen prioritization involved developing
a list of “ideal” cancer antigen criteria/characteristics and
assigning relative weights to those criteria using pairwise
c o m p a r i s o n s .T h er e s u l to fc r i t e r i aw e i g h t i n gw a sa sf o l l o w s :
(a) therapeutic function, (b) immunogenicity, (c) role of the
antigen in oncogenicity, (d) speciﬁcity, (e) expression level
and percent of antigen-positive cells, (f) stem cell expression,
(g) number of patients with antigen-positive cancers, (h)
number of antigenic epitopes, and (i) cellular location of
antigen expression [22]. Such an eﬀort to prioritize cancer
antigens represents the logical next step in attempting to
focus translational eﬀorts on cancer vaccine regimens with
the highest potential for success.
A biological issue limiting the eﬃcacy of cancer vaccines
is the low immunogenicity of cancer antigens. Strategies to
enhance antigen immunogenicity are discussed in a later
section.
3. Primingthe Immune System
DNA vaccines are simple vehicles for in vivo transfection
and antigen production. A DNA vaccine is composed of a
plasmid DNA that encodes the antigen of interest under
the control of a mammalian promoter (i.e., CMV-intA,
CMV immediate/early promoter, and its adjacent intron A
sequence) and can be easily produced in the bacteria [23].
The optimized gene sequence of interest is delivered to
the skin (intradermally), subcutaneum or to the muscle by
one of several delivery methods. Using the host cellular
machinery, the plasmid enters the nucleus of transfected
local cells (such as myocytes or keratinocytes), including res-
ident antigen presenting cells (APCs). Here, gene expression
from plasmid is followed by generation of foreign antigens.
Although the elucidation of all immunological components
involved following DNA immunization has not been entirely
achieved, the mode of action of plasmid DNA vaccines
appears twofold. DNA plasmids, which are derived from
bacteria, stimulate the innate immune system by interactingJournal of Biomedicine and Biotechnology 3
with Toll-like receptor 9 (TLR9) [24]), a receptor found on
APCs, although the diﬀerential expression of TLR9 in mice
and primate immune cells makes more complex their role
as adjuvants in primates. This nonspeciﬁc immune response
augments the antigen-speciﬁc immune response, where the
direct and indirect presentations of antigen to APCs are
involved. Two overarching models have been proposed. The
antigen encoded by the plasmid is produced in host cells,
either in professional APCs leading to direct priming of
immune responses or in nonprofessional cells from where
the antigen can be transferred to APCs leading to cross-
priming.
A series of studies intended to determine how such vac-
cines could work investigated the source of Ag presentation,
the immunological properties of the DNA itself, and the role
of cytokines in eliciting the immune responses.
Early studies showed that DNA delivery method aﬀected
the cell types that were transfected. Gene Gun (bombard-
ment of the epidermis with plasmid coated onto gold
microbeads) tended to directly transfect epidermal ker-
atinocytes and also Langerhans cells, which were shown to
migrate rapidly to regional lymph nodes [25]. In this case,
professionalAPCsweretransfecteddirectlyandbehaveasthe
source of Ag presentation.
Alternatively, intramuscular injection of plasmid pre-
dominantly led to transfection of myocytes. Myocytes lack
expressionofmajorhistocompatibilitycomplexclass(MHC)
II and costimulatory molecules and thus would not be
expected to prime T lymphocytes directly. Instead, immune
priming likely occurs by dendritic cells (DCs) [26, 27]
that presumably migrate to the site of DNA inoculation in
response to inﬂammatory or chemotactic signals following
vaccination [28, 29]. These DCs are thought to present
antigen by cross-presentation of extracellular antigen or
following direct transfection of plasmid DNA [26, 30].
Thus, in terms of induction of immunity, there is an
inﬂuence of the site and procedure used for injection, with
muscle and skin cells clearly able to act as antigen depots
but unable to prime the immune response. It is likely that
cross-presentation from these sites to APCs is the major
route to priming [26], but there is also evidence for direct
transfection of APCs, especially when delivery is to skin sites
through a gene gun [25]. The host-synthesized antigen is
then processed and presented by APCs in the context of both
MHC I and MHC II.
Antigen-loadedAPCstraveltothedraininglymphnodes,
where they present peptide antigens to na¨ ıve T cells, thereby
eliciting both humoral and cellular immune responses.
AlthoughplasmidDNAvaccinesvectorscaninduceantibody
and CD4+ T cell helper responses, they are particularly
suited to induce CD8+ T cell responses because they express
antigens intracellularly, introducing them directly into the
MHC I antigen processing and presentation pathway [31].
Whatever, the process that conveys antigens to the APC
seems highly eﬃcient since DNA vaccines, that produce only
very low levels of antigen, can induce all arms of the immune
response [32].
One lesson learned in the last years is that the devel-
opment of plasmid DNA as cancer vaccine raises key issues
such as the need to break immunological tolerance, gradual
loss of MHC and antigen in tumour cells, regulatory T cells
that could negatively inﬂuence the induction of antitumour
responses, systemic defects in dendritic cells, secretion of
immunosuppressive cytokines, resistance to apoptosis [33,
34] as is discussed elsewhere.
4. Advantages andDisadvantagesof
DNA Vaccines
TheuseofDNAvectorsrepresentsanimportantplatformfor
clinical applications, in which large-scale vaccine production
is not easily manageable with other forms of vaccine
including recombinant protein, whole tumor cells, or viral
vectors [35].
Although viral mediated gene transfer by geneti-
cally modiﬁed lentiviruses, adenoviruses, adeno-associated
viruses, and retroviruses is advantageous because of its high
transfection eﬃciency and stability [36], the largest hurdles
using viral vectors are to overcome the immunogenicity of
the viral packaging proteins. Furthermore, viral methods are
disadvantageous because of their high expense, toxic side
eﬀects, limits on transgene size, and potential for insertional
mutagenesis [37].
On the one hand, nonviral vectors are highly ﬂexi-
ble, are capable of encoding a number of immunological
components, are associated with a lower cytotoxicity, are
relatively more stable, and are potentially more cost-eﬀective
for manufacture and storage (Table 1).
Their safety in terms of adverse reactions after injection
has been demonstrated in animal models [38, 39]a sw e l la s
in human clinical trials.
The ﬁrst clinical trail, initiated to monitor the safety
and eﬃcacy of a DNA vaccine against HIV-1 infection [40],
demonstrated that DNA plasmid vaccines were safe and were
capableofinducingdetectableimmunecellularandantibody
responses [40–42].
The simple plasmid backbone coupled with the tech-
nology of gene manipulation allows incorporation of genes,
which are then expressed by cells transfected in vivo.
Although the transfection process is ineﬃcient and varies
with the target tissue and means of delivery, suﬃcient DNA
is generally taken up to prime the immune response [32].
DNA vaccines are free of the problems associated with
producing recombinant protein vaccines, and they are also
safer than live attenuated which can cause pathogenic
infection in vivo. Additionally, studies with DNA vaccines
have shown that even after multiple immunizations, anti-
DNA antibodies are not produced [43].
The ability to introduce antigen to the host immune
system, thus enabling it to elicit strong Th1 type CD4+ T
cells and CD8+ cytotoxic T cells, is a unique feature of
DNA vaccines which makes them distinct from conventional
protein or peptide vaccines. Because of this feature, they can
readily induce humoral as well cellular immune responses
[44].
Plasmid-based gene transfer can also deliver oligonu-
cleotides that can alter gene splicing or gene expression, for
example, siRNA [35, 45].4 Journal of Biomedicine and Biotechnology
Table 1: DNA vaccines main features.
Advantage Drawback
Design
Allowing the introduction of several immunological
components; synthetic and PCR methods for simple
modiﬁcations
Low transfection eﬃciency
Manufacture Rapid production and formulation; easily engineered,
reproducible, large-scale production and isolation
Safety
No pathogenic infection in vivo; no signiﬁcant adverse
events in any clinical trial; neutralizing immune
responses rarely observed; boost strategy is possible
Stability Long shelf life; relative temperature insensitivity; lack
necessity of a cold chain stored on a large scale
Immunogenicity Lower immunogeni-city in larger animals and
human compared to mice
5. EnhancingEfﬁcacyand Immunogenicityof
DNA Vaccines
Despite immunogenicity of DNA vaccines has been well
established in animal models, low immunogenicity has
been the major deterrent towards the development of DNA
vaccinesinlargeanimalmodelsandhuman.Inordertoover-
come this hurdle, several approaches have been investigated
including plasmid design, immunomodulatory molecules,
delivery techniques, and prime-boost strategy (Table 2).
5.1. Plasmid Design. Early in the development of DNA vac-
cines, it became clear that maximizing the expression of the
encoded Ag was critical to the induction of potent immune
responses. Strong viral promoters, such as CMV-intA, are
generally favoured over regulated or endogenous eukaryotic
promoters [70]. Furthermore nuclear targeting sequence
(NTS) could be introduced to increase the eﬃciency of
nuclear plasmid uptake from cytoplasm after intramuscular
injection [48, 71].
The utilization of codon-optimized sequences instead
of the wild-type coding sequences is a general and potent
methodtoimprovevaccination.Anoptimalcodingsequence
is determined back from the amino acid sequence of the
antigen by algorithms that take into account the abun-
dance of speciﬁc tRNAs in the cytosol of human cells
and the predicted structure of the mRNA. Thereafter the
selected gene sequence is constructed in vitro using synthetic
oligonucleotides. Adverse rare codons are avoided and
secondary structures in the mRNA are minimized. Thereby,
thesyntheticgeneisoptimalforexpressionandconsequently
for the induction of an immune response [72].
The ﬂexibility of plasmid design coupled with the
technology of gene manipulation allows also “gene opti-
mization.” Indeed, the variable regions of the heavy (VH)
and light chain (VL) of the tumor immunoglobulin, speciﬁc
for the B-cell malignancies, can be readily cloned and
combined into single-chain variable fragment (scFv) format,
encoding a single polypeptide consisting of VH and VL genes
linked together in frame by a short 15-amino acid linker
[73].
As already discussed, the backbone of bacterial DNA
includes cytosine-phosphate-guanine (CpG) unmethylated
regions as sequence motifs that stimulate innate immunity,
creating an inﬂammatory milieu for triggering the adaptive
immune response [74]. The role of CpG motifs as adjuvants
of immune response to DNA vaccines is well documented
in mice [75]. Preclinical studies showed that the addition
of CpG motifs in the plasmid can result in the induction
of proinﬂammatory cytokines, for example, IL-12 or IFN-
I[ 75]. CpGs are recognized by TLR9, a receptor found on
APCs, helping cytotoxic T-lymphocyte (CTL) diﬀerentiation
and priming. The coadministration of genes encoding
ligands for Toll-like receptors (TLRs) or their signaling
molecules has been shown to improve the immunogenicity
of DNA vaccines [66, 76].
Engineering DNA vaccine design for maximizing
epitope-speciﬁc immunity has allowed epitope enhancement
by sequence modiﬁcation. The recent molecular under-
standing of the immune response is leading to new strategies
to induce more eﬀective immune responses. Self-tolerance
might lead to deletion of T cells speciﬁc for the most eﬀective
epitopes, leaving only low-avidity T cells [77, 78]. Therefore,
not all sequences are optimal antigenic epitopes. A process
termed epitope enhancement is expected to make the
sequences of many epitopes of cancer more immunogenic
[79]. Epitope sequences can be modiﬁed to increase the
aﬃnity of the epitope peptide for the MHC molecule. The
knowledge of sequence motifs for peptide binding is the key
to improve the primary and/or secondary “anchor residues”
that provide much of the speciﬁcity of binding to the MHC
molecule [80, 81]. This strategy can greatly increase the
potency of a vaccine and can convert a subdominant epitope
into a dominant one by making it more competitive for
available MHC molecules, thereby increasing the level of
speciﬁcpeptide—MHCcomplexesontheantigenpresenting
cell surface [82]. Epitope enhancement has been used to
increase the aﬃnity for both MHC class I and class II
molecules (reviewed in [83]).
To enhance the immunogenicity of DNA, vaccines en-
coding immunostimulatory RNA, such as double-stranded
RNA or replicon RNA, were also generated [84].Journal of Biomedicine and Biotechnology 5
Table 2: DNA Vaccine Enhancing Strategies.
Strategy Approach Indication References
Routes of
administration
intramuscular/EP prostate cancer; B-cell
lymphoma
[46–48]
intradermal/EP prostate cancer; colon
cancer
[49, 50]
gene gun cervical cancer [51, 52]
tattoo perforating needle melanoma [53]
intratumor melanoma; renal
carcinoma
[54, 55]
high-pressure liquid delivery B-cell lymphoma; [50, 56]
colon cancer
Genetic
immunomodulators
as Adjuvants
cytokine
liver cancer; prostate
cancer; melanoma; B-cell
lymphoma
[56–62]
chemokine B-cell lymphoma [63]
T cell helper epitopes
prostate cancer; follicular
lymphoma; colon
carcinoma
[46, 47, 64, 65]
Toll-receptor ligands lung carcinoma [66]
heat shock proteins cervical cancer [67]
Prime-boost strategy
plasmid DNA/plasmid DNA+EP prostate cancer; colon
cancer
[46, 47, 50]
plasmid DNA/recombinant
protein
prostate carcinoma; breast
cancer
[68] NCT00363012
plasmid DNA/viral vector liver cancer; melanoma;
prostate carcinoma
[58, 60, 69]
viral vector/plasmid DNA prostate cancer [59]
Engineering vaccine design for manipulating antigen
presentation and processing pathways is one of the most
important aspect that can be easily handled in the DNA
vaccine technology. If an antibody response is the goal, it
is clearly desirable to direct antigen expression to the endo-
plasmic reticulum (ER), in which folding and secretion can
occur. An appropriate leader (signal) sequence can achieve
this. (reviewed in [47]). For induction of CTLs, addition
of genes encoding molecules such as ubiquitin, aimed to
enhance degradation and peptide production in the protea-
some, can be eﬀective (reviewed in [85]). Similarly, targeting
expression to diﬀerent subcellular pathways such as the
endosome or lysosome can amplify CD4+ T cell responses
[85]. Thus, DNA vaccines can be designed to induce an
appropriate eﬀector pathway, including antibody against
cell-surface antigens, or CTL response against intracellular
antigens expressed only as MHC class I-associated peptides.
Since tumor antigens are often weakly immunogenic and the
immune repertoire in patients may have been tolerized, the
central question is whether DNA vaccines can activate and
maintain the high level of immunity required to suppress
cancer cell growth.
ThepivotalpositionofCD4Thelper(Th)cellsinhelping
B cells to produce antibody and control induction and
maintenanceofCD8Tcells[86]hasledsomeinvestigatorsto
focus on their importance in responses to DNA vaccination.
By selecting genes encoding microbial proteins fused to
the tumor antigen sequence, it was possible to activate
Th cells and to dramatically amplify immunity against
tumor cells [87]. As discussed in the following section,
D N Av a c c i n e so ﬀer the opportunity to activate Th cells
and transform weak and ineﬀective immunity to a powerful
antitumor attack [88].
5.2. Immunomodulatory and Immunoenhancing Molecules.
Even though speciﬁc antibody and CTL responses could be
induced in clinical trials with naked DNA vaccines, by the
intramuscular or intradermal route, high doses of DNA were
necessary to elicit detectable immune responses [89, 90].
Largequantities,thatis,5–10mg,arerequiredtoinduceonly
modest immunogenicity [91].
Modifying the microenvironment of the vaccinated site
bycoadministrationofgenetic,thatis,DNAplasmidscoding
for immunostimulatory molecules, protein, or chemical
adjuvants, improves the low immunogenicity of DNA vac-
cines [31].
Progress has been made in developing improved tech-
niques for encapsulating plasmid DNA (liposomes, poly-
mers,andmicroparticles)althoughfewoftheseformulations
havebeenshowntoelicitimmuneresponsesthataresuperior
to those elicited by simple intramuscular plasmid DNA, still
disappointing in human clinical trials [92].
Considering the ease in design and construction of
plasmidDNAusedtotargetaparticularneoplasm,biological6 Journal of Biomedicine and Biotechnology
Table 3: Adjuvant molecules employed in cancer clinical trials to
enhance the immune response.
Adjuvant Phase References
Genetic
cytokines I/II-II NCT00019448
(GM-CSF, IL-12, IL-2) [56, 62]
bacterial toxins I/II [46, 47, 64, 65]
(pDOM/tetanus toxin FrC)
immunomodulatory
molecules (HSP70)
I/II [67]
Protein cytokines (GM-CSF, IL-2) I/II-II [58, 59, 61];
adjuvants can be tailored and encoded within the same DNA
vectoraswell[35].Avastarrayofmoleculesabletomodulate
immune responses can be delivered (Table 3).
They include chemokines to attract APC [93], activating
cytokines [94, 95], costimulatory molecules, APC-targeting
antibodies, and molecules to manipulate antigen presenta-
tion and/or processing [96].
OneofthecommoncytokinesemployedinplasmidDNA
vaccine is granulocyte–macrophage colony–stimulating fac-
tor (GM-CSF), a molecule able to enhance immune
responses by inducing proliferation, maturation, and migra-
t i o no fD C sa sw e l la se x p a n s i o na n dd i ﬀerentiation of B and
Tl y m p h o c y t e s[ 62].
In addition to codelivery, DNA vaccines allow fusion of
genes encoding activating molecules to the antigen-encoding
sequence. This is an advantage, and fusion genes can create
single vaccines capable of multiple functions.
Biragyn and colleagues showed that the eﬃciency of
DNA vaccination in vivo could be greatly increased by
encoding a fusion protein consisting of scFv fused to a
proinﬂammatory chemokine moiety that facilitates targeting
of APCs for chemokine receptor-mediated binding, uptake,
and processing of scFv antigen for subsequent presentation
to CD4+ or CD8+ T cells, or both [63]. In two independent
models, vaccination with DNA constructs encoding a fusion
proteinconsistingofscFvfusedtothemonocytechemotactic
protein 3 (MCP-3) or the interferon inducible protein 10
(IP-10a) generated superior protection against a large tumor
challenge (20 times the minimum lethal dose), as compared
with the best available protein vaccines [63].
Additional strategies to activate eﬀective immunity
against poorly immunogenic tumor antigens employ the
“DNA fusion genes vaccines” to activate T cell help for
antitumor responses. The CD4+ Th cell, as pivotal cell of the
immuneresponseabletoinducehighlevelsofimmunityand
themaintenanceoftheresponse,hasbeenextensivelystudied
by Stevenson and coworkers [97]. The requirement for
foreign sequences to induce Th for the B-cell response and to
help the CTL response has been known for many years [98,
99].SinceThcellscontrolresponsestovaccination,itisquite
obvious that self-antigens, which do not contain epitopes
likely to be recognized by available Th cells, are incapable
of inducing immunity. A strategy to activate Th cells for
inducing antitumor immunity is to engage a repertoire
against nontolerized antigens. The use of xenogeneic antigen
to break tolerance is likely due to the presence of some
foreign sequences in the xenogeneic antigen that are able
to activate Th cells [100]. Focusing on the antimicrobial
repertoire, the principle has been applied to realize the DNA
fusion gene vaccines encoding the tumor antigen linked
to an antigen derived from tetanus toxin. Fusion of the
Fragment C (FrC) of tetanus toxin ampliﬁed the immune
response against a range of tumor antigens, leading to
suppression of tumor growth [87]. Clinical trials by using
these approaches to breaking self-tolerance for therapeutic
purposes in patients with lymphoma and prostate carcinoma
are discussed elsewhere.
5.3. Route of Administration. It is increasingly apparent that
the immunogenicity of DNA vaccines greatly depends upon
the delivery methods used for immunization [101].
In a melanoma mouse model, DNA vaccination was
administered together with intratumoral delivery of antian-
giogenic plasmids, encoding angiostatin, and endostatin.
Combined melanoma vaccination resulted in 57% tumor-
free survival over 90 days after challenge [54]. In a modest
proportion of patients with malignant disease, intratumoral
injection of DNA led to regression of tumor at distant sites
[102].
The recent studies have conﬁrmed that physical methods
are superior over other delivery methods that administer
DNA in various chemical solutions [103, 104].
Biolistic gene gun delivery involves adhering naked DNA
to gold beads and shooting the particles through a high-
pressured instrument. This system delivers DNA directly
into skin and Langerhans cells in a highly eﬃcient process.
Gene gun immunization has been shown to induce a greater
CD8+ Tc e l lr e s p o n s ea sw e l la st or e q u i r el e s sv a c c i n et o
achieve tumor immunity [51].
A promising strategy is electroporation (EP), which in
primates increases not only the level but also the breadth of
response [105], overcoming the diﬃculty in translating the
eﬀectiveness of DNA vaccination from preclinical rodents to
large animals, including human subjects [106].
Electroporation-basedDNAdeliverytechnologydramat-
ically enhances cellular uptake of DNA vaccines. EP itself
works as an adjuvant to enhance the necessary “danger
signals” that become detectable by the immune system.
The tissue damage caused by the application of EP causes
inﬂammation and recruits DCs, macrophages, and lympho-
cytes to the injection site [107, 108] inducing signiﬁcant
immune responses, including antibody and T-cell responses.
Moreover, it is tolerable without anesthetic and does not
induce unwanted immune responses against the delivery
mechanism, therefore it can be used for repeat administra-
tions.
A newly developed intradermal DNA delivery is the
tattoo technology. The tattoo device has a cartridge of nine
ﬁne metal perforating needle that oscillate at a constant high
frequency and puncture the skin, leading to DNA transfer
to skin-associated cells. The expression of reporter genes
results in robust T-cell responses [109]. Recently tattoo-
immunization was applied in a phase I study to assessJournal of Biomedicine and Biotechnology 7
the toxicity and eﬃcacy of inducing tumor-speciﬁc T-cell
immunity against melanoma [53].
5.4. Prime-Boost Strategies. Vaccination schedules based on
combined prime-boost regimens using diﬀerent vector sys-
tems to deliver the desired antigen (i.e., heterologous prime-
boost immunization regimen) appear to be a successful
improvement in DNA vaccine platform.
Actually, prime-boost regimens have shown promise in
elicitinggreaterimmuneresponseinhumanscomparedwith
DNA vaccination alone [101].
The DNA-prime-viral vector-boost approach focuses on
the induction of T-cell immune responses. In this approach,
homologous boost immunization carries the equivalent
antigen than the previous immunization. Viral vectors that
have been tested as booster vaccine include adenovirus,
vaccinia virus, fowlpox [110, 111] as well as recombinant
vesicular stomatitis virus [112].
Likewise, the DNA-prime-protein-boost approach em-
ploys recombinant protein antigens that match with the
antigens used in DNA prime immunization [68, 113, 114].
This strategy aims to develop balanced humoral and cell-
mediated immune responses with a focus on eliciting high
quality protective antibody responses.
The heterologous prime-boost vaccination regimen
exploits the ability of the immune system to generate a
largenumberofsecondaryantigen-speciﬁcTcells.Following
a priming immunization, a proportion of the antigen-
speciﬁc T cell population transforms into antigen-speciﬁc
memory T cells, which have the ability to expand rapidly
upon encounter with the same antigen a second-time
round.
Since the priming and boosting vectors are diﬀerent,
this strategy allows for greater expansion of the disease
antigen-speciﬁc T cell populations [115]. To date, heterol-
ogous prime-boost regimens are among the most potent
strategies to induce cellular immune responses. Compared
to homologous prime-boost approach with the same DNA
vaccine, boosting a primary response with a heterologous
vector will result in 4–10-fold higher T cell responses [116–
118].
On the one end, a combination of DNA vaccines with
EP in a homologous prime-boost approach could generate
antibody responses comparable to those that are induced
by protein in Complete Freund Adjuvant, and also ampli-
ﬁed CTL responses [46]. EP may provide a prime-boost
combination equivalent to that observed using viral vectors,
and it is now undergoing testing in the clinic using a DNA
vaccine for patients with prostate cancer. Repeated EP has
been accepted by patients without the need for general or
local anaesthesia and with no apparent long-term ill eﬀects
[47].
5.5. Strategies to Break the Immunosuppressive Networks.
Immune suppression is a feature of the tumor microen-
vironment and a barrier to tumor immune therapy. The
microenvironment of tumors is established through the
activity of both myeloid and lymphoid regulatory cells,
as well as through the production of immune-suppressive
factors by malignant cells themselves.
Many tumor-inﬁltrating macrophages, referred to
myeloid-derived suppressor cells (MDSCs), have an im-
mune-suppressive phenotype [119]. These macrophages
are abundant in many tumors arising in both humans and
mice and can exert powerful anti-inﬂammatory eﬀects. In
addition to MDSCs, regulatory T cells (Tregs) also heavily
inﬁltrate many tumors [120]. These cells, characterized by
the expression of the transcription factor FoxP3 as well as
CD4 and CD25, play a key role in the regulation of adaptive
immunity. Tregs can suppress immune responses through
the secretion of suppressive cytokines like TGF-β and IL-
35 [120, 121]. Tregs are a potential barrier to developing
productive immune therapies for cancer, and they represent
an attractive target for enhancing antitumor immunity.
Cancer immunotherapy is designed to speciﬁcally target
cancer types using components of the immune system.
Therefore DNA vaccines are also faced many obstacles that
include breaking peripheral T cell tolerance against tumor
self-antigens, to elicit appropriate immune reactions, as well
as overcoming tumor-derived immunosuppressive networks
and evasion tactics. Evasive mechanisms adopted by malig-
nant cells to prevent immune cell function are numerous
and lead to the clonal expansion of non-immunogenic
tumor cells, by loss of tumor antigen, and to the apoptosis
prevention [35].
Tumour cells can downregulate expression of MHC
and target antigens and often secrete immunosuppres-
sive molecules to defend themselves against attack [122].
Tumourscancreateatolerogenicenvironmentwhichspreads
to draining lymph nodes and can enhance regulatory T-
cell activity. The hurdles to successful reversal of tolerance
and induction of eﬀective immunity are becoming clear
and vaccines must incorporate elements to overcome them
[123].
Furthermore cancer cells secrete soluble factors in the
tumor microenviroment, for example, VEGF, IL-10, and
TGF-β, that aﬀect the maturation, diﬀerentiation, and
activity of APCs as DCs [124], interfering with immune cells
maturation and eﬀector properties. The tumour microen-
vironment may drive tumour growth and even selectively
support a subset of tumour cells, the cancer stem cells
(CSCs).
The DNA vaccination platform can be capable of
suppressing the progression of already established tumor
by targeting those secreted soluble factors in the tumor
microenvironment [125], reversing immunological attenua-
tion mechanisms and improving DNA vaccine potency.
The concept of combining cancer vaccination with
angiogenesis inhibition is appealing, due to favorable safety
proﬁle of both approaches, as well as possible biological
synergies [54]. DNA vaccination in mice against the VEGF
receptor, FLK-1, abrogated the tumor vasculature and
protected DNA vaccinated animals from tumor challenge
in prophylactic approach [126]. Expression of the platelet-
derived growth factor receptor (PDGFR) in stromal cells
directly correlates with advanced stage disease in human
colorectal cancer. DNA vaccine against PDGFRβ suppressed8 Journal of Biomedicine and Biotechnology
growth and dissemination of human colorectal cancer cells
injected into mice [127].
In vivo coadministration of plasmids encoding the
chemokine macrophage inﬂammatory protein-1alpha (MIP-
1alpha) and the DC-speciﬁc growth factor fms-like tyrosine
kinase 3 ligand (Flt3L) with the plasmid DNA augments the
immunogenicity of the vaccine, mobilizing and activating
large numbers of DCs at the site of inoculation [128].
Consistent with the concept that most eﬀective cancer
therapies are multimodal, combining Treg depletion with
active cancer immunotherapeutic interventions is an attrac-
tive prospect, supported by abundant data in mice [129–
132] and by preliminary human trials [133–135]. Lastly,
additional strategies aimed to altering regulatory T cell
function in cancer immunotherapy, including blocking Treg
traﬃcking, diﬀerentiation, and/or function and reducing
eﬀectorcellsusceptibilitytosuppression,havealreadyproven
successful in preliminary studies [136–138].
6.HumanClinicalTrials
The goals of the various clinical trials were to demonstrate
the safety and tolerability of the candidate vaccines, and to
explore the eﬃcacy of DNA vaccines in humans. Injection
of the plasmid DNA construct is tolerated well in terms
of safety in the patient population and rarely involves
systemic toxicities. DNA vaccines that are currently being
tested do not show relevant levels of integration into host
cellular DNA [139, 140]. Besides, preclinical studies in
nonhuman primates as well as early studies in humans did
not detect increases in antinuclear or anti-DNA antibodies.
Participants in human trials of DNA vaccines are followed
for possible signs and symptoms of autoimmunity induced
by DNA vaccination giving no convincing evidence of
autoimmunity developing in association with a DNA vaccine
[40, 42, 141].
The earliest Phase I clinical trial for a DNA vaccine was
of an HIV-1 candidate tested in individuals infected by HIV-
1, followed by studies in volunteers who were not infected
by HIV-1 [40]. Other prophylactic and therapeutic DNA
vaccine trials followed, including trials that tested DNA vac-
cines againstcancerinﬂuenza, malaria, hepatitis B, and other
HIV-1 candidates [24, 41, 42] .T h e s et r i a l sd e m o n s t r a t e d
that the DNA vaccine platform is well tolerated and safe,
as no adverse events were reported and all studies went to
completion.
TheevidentsafetyofDNAvaccineshasledtoarelaxation
of the requirements for approval by both the United States
Food and Drug Administration and the national competent
regulatory authorities in Europe. This is why many clinical
studies tend to melt the ﬁrst phase with the second phase.
Then the issue has become the eﬃcacy rather than toxicity.
Since tumour antigens are generally weakly immuno-
genic,theyofteninducealowlevelofspontaneousimmunity
or, in other cases, the spontaneous response can lead to
tolerance [47]. The molecular precision oﬀered by gene-
based vaccines, together with the facility to include addi-
tional genes to direct and amplify immunity, could lead to an
eﬃcient methods to use the immune system against cancer.
The inclusion of FrC sequence, or other nonself antigens,
activates T-cell help to reverse tolerance and induces high
levels of immunity [47, 64, 65]. To further increase immuno-
genicityofDNAvaccine,theuseofmolecularadjuvantssuch
as cytokines and immunomodulatory molecules has been
extensively employed in clinical trials [56, 58–63, 67].
Clinical trials conducted over the last few years have
led promising results, particularly when DNA vaccines
were used in combination with other form of vaccines, as
demonstrated in prostate and liver cancer clinical trials [58–
60,68].Deliveryofgene-basedvaccinesbyphysicalmethods,
that is, electroporation and gene gun, has demonstrated
to amplify the immune responses induced by therapeutic
vaccines against cancer [46, 47, 64].
In the following section, an overview of various types of
clinical trials will be given to highlight the issue for usage of
plasmid DNA in humans. Table 4 provides a brief summary
of clinical trials discussed in this review.
6.1. Lymphoma. DNA vaccination is an attractive and eﬀec-
tive approach for active therapeutic vaccination against B-
cell malignancies given the ease of production compared to
Id protein vaccines.
Patient-speciﬁc DNA vaccines for therapy of B cell
lymphomas and multiple myelomas based on scFv encoding
a chimeric immunoglobulin molecule consisting of VH and
VL genes derived from each patients’s tumor were shown to
be eﬀective in animal models [47, 73].
The ﬁrst phase I/II trial of idiotypic vaccination for fol-
licular B-cell lymphoma using a genetic approach [142]w a s
conducted by Hawkins and colleagues. Vaccines encoding
individualDNAidiotypicscFvfusedtoTTFrCweredelivered
as naked DNA by i.m. injection in patients with follicular
lymphoma in clinical remission following chemotherapy,
and plasmid DNA were able to develop cellular or/and
humoral antiidiotype immune responses in 38% of patients
over a period of several months [47].
In a second study of vaccine therapy for B-cell lym-
phoma, the patient’s tumor scFv was linked to the IgG2a and
κ mouse immunoglobulin heavy- and light-chain constant
regions chains, respectively. In this phase, I/II trial patients
in remission after chemotherapy received two series of i.m.
DNA vaccinations and at the end of the second vaccination,
50% of patients exhibited humoral and/or T-cell anti-Id
responses; yet, these were cross-reactive with Id proteins
from other patient’s tumors. Subsequently, a third series of
vaccinations was carried out using human GM-CSF DNA
mixed with Id DNA: humoral or T-cell responses were
boosted in some cases [56].
6.2. Prostate Carcinoma. After the important insights pro-
videdinpreclinicalstudies[49],thedepartmentofOncology
of the University Hospital of Uppsala is recruiting partici-
pants for a phase I/II trial, where intradermal EP (DERMA
VAX) will be used as a delivery system. This study will assess
the feasibility and safety of vaccination with increasing doses
of xenogenic DNA coding for the Rhesus Prostate Speciﬁc
Antigen (rhPSA), a protein that is 89% homologous toJournal of Biomedicine and Biotechnology 9
human PSA, administered in patients with relapsed prostate
cancer.
A phase I/II, dose escalation, DNA vaccination trial with
plasmid DNA, which carries prostate-speciﬁc membrane
antigen (PSMA), fused to a domain (DOM1) of Fragment
C of tetanus toxin, delivered either by i.m. or by i.m.
followed by EP, was performed in patients with recurrent
prostate cancer. The epitope used in this study, PSMA27
is a short stretch of 9 amino acids tumor-derived epitope
belonging to the PSMA. Preliminary analysis of CD8+ T-
cellreactivityagainsttheprostate-speciﬁcmembraneantigen
target peptide indicated signiﬁcant responses in 3 out of
3 patients and CD4+ T-cell responses against the DOM1.
These data validated EP as a potent method for stimulating
humoral responses induced by DNA vaccination in humans
[46, 47, 64].
Results of a phase I/II trial, conducted with DNA vaccine
encoding human prostatic acid phosphatase (PAP) coad-
ministered intradermally with GM-CSF, in prostate cancer
patients (stage D0) are associated with an increased PSA
doubling time (PSADT), 6.5 months pretreatment versus 9.3
months in the 1 year posttreatment [61]. A longer PSADT is
associated with an extremely low risk of death from prostate
cancer. Besides, 14% of patients developed PAP-speciﬁc
IFN gamma-secreting CD8+ T-cells immediately after the
treatment course, and 41% of patients developed PAP-
speciﬁc CD4+ and/or CD8+ T-cell proliferation, conﬁrming
the preclinical studies [143].
Todorova and colleagues[58] enhanced the DNA vaccine
eﬃcacy by heterologous prime-boost regimen in a Phase
I/II study. Prostate cancer patients were prime-boosted
with alternate injections of recombinant adenoviral vector
expressing PSMA and plasmid DNA encoding PSMA and
CD86 alongside receiving GM-CSF proteins as adjuvants.
After 36-month observation period from the ﬁrst vaccine
injection, 86% of participants developed anti-PSMA anti-
body.
6.3. Melanoma. DNA vaccine platform is a promising
therapeutic approach also for the treatment of malignant
melanoma, as demonstrated by already completed and on-
going clinical trials.
In stage IV melanoma patients, a phase I/II pilot study
of intranodal delivery of Synchrotope MA2M plasmid DNA
vaccine induced both humoral and CTL responses against
cells expressing tumor two melanoma-associated antigens
[144]. Synchrotope MA2M plasmid is a bivalent DNA
vaccine encoding epitopes for both Melan-A (MART-1) and
tyrosinase with potential antineoplastic activity.
The same approach was used in a improved trial con-
ducted with the Synchrovax SEM plasmid DNA vaccine
containing a plasmid pSEM that encodes 4 peptide epitope
sequences, Melan-A (26–35), Melan-A (31–96), tyrosinase
(1–9),andtyrosinase(369–377),resultinginantigen-speciﬁc
immunity even though not induce regression of established
disease [145].
DNA plasmids encoding the gp100 nonmutated melano-
ma-melanocyte antigen alone were administered in patients
with metastatic melanoma. Rosenberg et al. showed that
neither intramuscular nor intradermal injection was capa-
ble of raising cellular immune reactivity or a signiﬁcant
incidence of antitumor eﬀects [57]. Increasing results were
obtained in a phase II study with interleukin-2 cytokines
as adjuvant used in combination with same vaccination
protocols (ClinicalTrials.gov Identiﬁer: NCT00019448)a n d
in a phase II trial with human GM-CSF plasmid DNA in
conjunctionwithamultipeptidevaccineencodinggp100and
tyrosinase peptidse [62].
6.4.CervicalCancer. Currentvaccinationstrategiesarebased
on the induction of neutralizing antibodies against the
major and minor capsid proteins, L1 and L2, of human
papillomavirus, and Gardasil is only eﬀective against a subset
of HPV genotypes [146]. Further therapeutic interventions
for early-stage and late-stage cervical cancers or HPV-related
disease are uneﬀective.
DNA plasmid platform could represent an ideal vaccine
against HPV infections since it could generate both humoral
i m m u n er e s p o n s et op r e v e n tn e wi n f e c t i o n sa sw e l la sc e l l -
mediated immunity to eliminate established infection [146].
A recent phase I/II clinical trial in patients with
high-grade squamous intraepithelial lesion associated with
HPV16 provided DNA plasmid expressing a mutated non-
functional E7 incapable of binding retinoblastoma protein,
with no transforming activity, linked to HSP70. A signal
sequence was also attached to the hybrid antigen which
results in secretion of the linked E7 antigen [67]. E7 HPV
antigen as well as E6 antigen are essential for transformation
and are coexpressed in HPV-associated lesions hence they
representidealtargetsforthedevelopmentofHPVtherapeu-
tic vaccines.
6.5. Liver Cancer. In preclinical studies, mice were suc-
cessfully DNA-based immunized [147]. In a prime-boost
approach, coadministration of plasmids DNA encoding
murine alpha fetoprotein (AFP) and murine GM-CSF was
followed by boosting with an AFP-expressing nonreplicating
adenoviralvector[60]leadingtotumorprotectiveimmunity.
The early studies were applied in a phase I/II clinical
trial in patients with HLA-A
∗0201-expressing stage II–IVA
hepatocellular carcinoma. Vaccine therapy, comprising AFP
and sargramostim (GM-CSF) plasmids DNA, followed by
AFP adenoviral vector boost determined the dose-limiting
toxicity and maximum tolerated dose of adjuvant vaccina-
tion (ClinicalTrials.gov Identiﬁer: NCT00093548).
6.6.BreastCancer. SinceHER-2/neu(HER2)oncogenicpro-
tein is a tumor antigen in patients with breast and ovarian
cancer, several vaccine strategies have been developed and
are being evaluated for safety and immunogenicity in phases
I and II clinical trials (ClinicalTrials.gov). Patients whose
tumors overexpress the antigen have both detectable anti-
body and T-cell immunity directed against HER2. Likewise
preclinical studies suggest that the HER2 protein, particu-
larly the intracellular domain (ICD), is a tumor rejection
antigen [148].10 Journal of Biomedicine and Biotechnology
Table 4: Phases I/II-II clinical trials: key summary.
Tumor Study ID Patients no. Objectives Status Response Side eﬀects
Lymphoma
Determine the safety, Absence of toxicity
UK-007 25 dose, immunogenicity Completed Cellular and/or
humoral responses
Prostate cancer
Determine the feasibility
and safety
Determine the safety and Open
NCT00859729 18 functionality of DNA recruiting
vaccine delivery system
Determine the Absence of toxicity Brief and
feasibility and safety Open CD8+ T-cell acceptable
UK-112 20 Determine the reactivity against the pain at the
immunological responses target peptide injection site
PAP-speciﬁc IFN
gamma-secreting
NCT00582140 22 Determine the safety Completed CD8+ T-cells
(Aug 2009) PAP-speciﬁc
CD4+ and/or CD8+
T-cell proliferation
Bulgarian Characterize the humoral Speciﬁc humoral
Drug 52 immune response Completed immune response
Agency Register against PSMA against PSMA
Melanoma
Determine the safety Antigen-speciﬁc
Grade I/II toxicity
and tolerability Immunity
NCT00033228 6–18 Determine the Completed No regression of
immunological and (July 2009) established disease
clinical responses
Determine the safety Open Immunological
Grade I toxicity
and tolerability Not eﬃcacy
NCT00085137 3–27 Determine any Recruiting in terms of
antitumor response T-cell response
Determine the feasibility
and toxicity Absence of
Determine the eﬀect toxicity
Determine changes In the highest-dose
in lesion size and Open cohort the number
HPV viral load Not of patients with
Cervical cancer NCT00121173 150 Determine the immune Recruiting complete histologic Transient
responses regression is injection-site
Correlate measures of higher than the discomfort
immune response with unvaccinated cohort,
clinical response but not signiﬁcant.
Determine the dose-
limiting toxicity and
maximum tolerated dose
Liver cancer NCT00093548 3–25 Determine the optimal Completed Absence of
biological dose (Feb 2009) toxicity
Determine disease-free
survival of patients treated
Determine and
characterize
Breast cancer NCT00363012 56 the immunologic Open Absence of
memory recruiting toxicity
to the HER2-ICDJournal of Biomedicine and Biotechnology 11
Salazarandcolleaguesarestudyingtheimmune response
in patients overexpressessing HER2 epitope who have
undergone vaccine therapy in a heterologous prime-boost
regimen (ClinicalTrials.gov identiﬁer: NCT00363012). After
vaccination with a plasmid encoding HER2 ICD in patients
withadvancedstageHER2overexpressingbreastandovarian
cancers patients receive HER2 ICD protein treatment intra-
dermally at 6 months postvaccination with the pNGVL3-
hICD vaccine. The injection site is biopsied and examined
forinﬁltratingT-cellandantigen-presentingcellpopulations
and blood samples are examined for the presence of memory
markers to demonstrate the development of HER2 ICD
memory immunity.
7. Conclusions andFutureDirections
Plasmid DNA is a new generation biotechnology product
that is just beginning to enter the marketplace. Progress
in the application of DNA vaccines as an immunization
protocol is evident from the increasing number of such
vaccines under evaluation in clinical trials and by the recent
approval of several DNA vaccine products for veterinary
applications.
The goal of DNA vaccination will be the development
of eﬀective immunization strategies against previously estab-
lished tumors. Because of tolerance to tumour antigens,
eﬀorts are ongoing to optimize the DNA vaccine technology
platform. Strategies to improve antigen expression, inclusion
ofadjuvantsintheformulation,orasimmunemodulatorsto
improve the immunogenicity, and the use of next-generation
delivery methods are under intensive investigation. Current
eﬀort to prioritize cancer antigens represents the logical
next step in attempting to focus translational eﬀorts on the
most promising cancer antigens into vaccines for cancer
treatment or prevention. It is likely that these vaccines
will have to be combined with other treatment modalities.
It has become appreciated that vaccine approaches may
enhance subsequent responses to radiotherapy and that
certain chemotherapies actually enhance responses to vac-
cines. Accordingly, several late-stage clinical trials are already
evaluating the beneﬁt of vaccination in addition to conven-
tional chemotherapy. One attractive setting is in patients
duringcompleteremissionafterstandardadjuvanttreatment
(chemotherapy, radiotherapy, etc., or a combination) to
whom vaccination can be given after immunological recov-
ery [149]. Combining immunotherapy with conventional
chemotherapy,antiangiogenictherapy,andotherapproaches
could yield synergistic or additive therapeutic results.
There is still much to do in terms of optimizing vaccine
design, activation and selecting appropriate target antigens,
improving immune recruitment, and delivery technology.
Nevertheless, in the next years an increasing number of
DNA vaccines will enter more advanced phases of human
studies, aimed to establish their eﬃcacy as real clinical prod-
ucts. Therapeutic regimens composed of optimal vaccine
formulations with combinations of immunotherapy agents
and delivery strategies could oﬀer hope to patients suﬀering
fromincurablecancerthatcurrentstandardtherapiescannot
provide alone.
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